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ABSTRACT 
Aims 
The objective of this paper is to determine the incidence of ophthalmic disease potentially 
leading to optic nerve disease in Middle Tennessee. 
Methods 
We use a retrospective population-based incidence study design focusing on the population of 
middle Tennessee and its nearby suburbs (N=3 397 515). The electronic medical records for all 
patients evaluated or treated at a large tertiary care hospital and clinics with an initial diagnosis 
of a disease either affecting the optic nerve, or potentially associated with optic nerve disease, 
between 2007 and 2014 were retrieved and analyzed. 
Results  
18 291 patients (10 808 F) with 18 779 incidence events were identified with an age range of 0-
101 years from the query of the Vanderbilt BioVU. Estimated age-adjusted incidence per 100 
000 population per year was 198.4/145.1 (glaucoma F/M), 14.4/11.4 (intrinsic optic nerve 
disease F/M), 10.6/5.8 (optic nerve edema F/M), 6.1/6.6 (orbital inflammation F/M), and 23.7/6.7 
(thyroid disease F/M). Glaucoma incidence was strongly correlated with age with the incidence 
sharply increasing after age 40. Optic nerve edema incidence peaked in the 25-34 old females. 
African American population has increased likelihood of glaucoma, orbital inflammation, and 
thyroid disease.  
Conclusions  
Mapping the incidence of pathologies of the optic nerve is essential to the understanding of the 
relative likelihood of these conditions and impacts upon public health. We find incidence of optic 
nerve diseases strongly varies by gender, age, and race which have not been previously 
studied using a unified framework or within a single metropolitan population  
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INTRODUCTION 
Incidence of optic nerve related ophthalmic disease is an important area for study 
as a host of conditions have the propensity to result in optic nerve damage, which often 
leads to irreversible vision loss and visual disability. Some of these processes are acute 
and may present with rapid visual deterioration (ischemic optic neuropathy, optic 
neuritis as examples), while others are more insidious and manifest over time (chronic 
open angle glaucoma). While these diseases may not initially present with optic nerve 
dysfunction in earlier stages on a clinical level, each disease process lends itself to 
compromise optic nerve integrity, resulting in optic nerve injury.  
Mapping the incidence of pathologies of the optic nerve is essential to 
understanding the relative likelihood of these conditions and gives a framework upon 
which to target treatment.  While several population-based studies have evaluated 
incidence and prevalence of various pathologic ophthalmic conditions one at a time1-6, 
none have evaluated multiple disease processes in a diverse population base covering 
a large geographic area with rural and metropolitan components.  
Electronic medical records (EMRs) offer the opportunity to glimpse at the health 
histories of millions of individuals without requiring centralized reporting of disease (i.e., 
registries). The focus of this paper is to characterize the incidence of five distinct 
ophthalmic conditions impacting the middle Tennessee area using the Vanderbilt 
University Medical Center (VUMC) anonymized (Synthetic Derivative) medical records. 
We evaluate the incidence of ophthalmic conditions affecting optic nerve function in five 
major disease cohorts: glaucoma5, 7-9, intrinsic optic nerve disease2, 6, 10-12, optic nerve 
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edema (and idiopathic intracranial hypertension)3, 4, 13-15, orbital inflammation16-19, and 
thyroid disease1, 20, 21. The cohorts were investigated (as opposed to specific diagnoses) 
to ensure reliable patient-group assignment across thousands of patients without expert 
chart review of individual patients.  
METHODS 
Study Population  
Nashville and its surrounding suburbs make up the most densely populated area 
in Tennessee. VUMC (in Nashville, TN) captures a large proportion of the patient base 
within the middle Tennessee corridor (including the Nashville metropolitan area), 
specifically zip codes with the three-digit prefixes 370, 371, 372, 373, 374, 383, 384, 
and 385. Based on 2010 US Census data22, these areas have a combined population of 
3 397 515; age by sex distributions were retrieved to facilitate more detailed 
investigation of incidence rates. Herein, we limit our focus to United States (US) zip 
codes for this middle TN catchment area. De-identified data from patients diagnosed 
with the diseases of interest were identified from the Vanderbilt Synthetic Derivative 
database (Fig. 1). This database contains the electronic medical records for over 2.2 
million unique individuals. The search interface allows the user to input basic clinical 
and demographic information, such as International Classification of Diseases version 9 
(ICD-9) codes, Current Procedural Terminology (CPT) procedure codes, medications, 
lab values, age, and gender. Note the census population estimate is for the median 
study year. From 2011 – 2013, 46% of patients admitted for an ophthalmic condition 
were admitted to VUMC as opposed to other area hospitals based on Tennessee state 
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maintained inpatient hospitalization records of patients residing in the indicated zip 
codes (total events: 9 568), Prior hospitalization records with this level of detail were not 
available, and subsequent records had not been released as of the time of this study. 
Therefore, reference population estimates from the census data were scaled 
accordingly (e.g., market-adjusted population). The protocol, compliant with the Health 
Insurance Portability and Accountability Act (HIPAA), was approved by the Institutional 
Review Board of Vanderbilt University. The study adhered to the tenets of the 
Declaration of Helsinki.  
Data Collection 
The ophthalmic conditions investigated in this study (glaucoma, intrinsic optic 
nerve disease, optic nerve edema, orbital inflammation, and thyroid disease) were 
defined by ICD-9 codes (Table 1). De-identified demographics (age, sex, ethnicity, and 
race) and all ICD-9 events (date / code pairs) were retrieved for all patients with ICD-9 
codes matching Table 1 from the VUMC BioVU Synthetic Derivative (33 494 patient 
records with 4 286 224 ICD-9 events). The earliest records dated from 1994, but full 
adoption of the electronic medical record system did not take place until 2004. 
Therefore, 2007 was selected as the first year to minimize the misinterpretation of 
follow-up visits as initial diagnosis events. The BioVU Synthetic Derivative removes 
protected health information in the form of dates by time-shifting all events for each 
patient by a random (but fixed per patient) number of days. Patients retained for study 
met the following criteria: (1) had an office visit between the years 2007 and 2014, (2) 
had initial diagnosis of one of the ICD-9 codes of interest within the time range, (3) 
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resided in the geographical region of interest (zip code prefix of 370, 371, 372, 373, 
374, 383, 384, and 385), and (4) had complete age and gender information. The data 
from 2014 was not included in the final analysis as all of the data from 2014 was not 
available. For the purposes of this study, the date of occurrence of a condition was 
defined as the date of the first ICD-9 code with a cohort. 
Data Analysis and Statistical Methods 
To ensure sufficient sample size, patients were binned according to 13 age 
groups represented in the US Census data (i.e., 0-4, 5-9, 10-14, 15-19, 20-24, 25-34, 
35-44, 45-54, 55-59, 60-64, 65-74, 75-84, 85+ years of age). Note that the patient age is 
the age at time of initial diagnosis with an ICD-9 code within one of our five cohorts. A 
patient may belong to multiple groups if they had multiple conditions within the period of 
this study; note that the age of a patient could be different in different groups if the 
conditions occurred at different time points. The annual incidence rate was calculated 
by dividing the count of newly diagnosed patients within each time interval (e.g., total 
divided by 7 years for the complete study) by the estimated market-adjusted population 
(Fig. 1). Note that this approach averages both the incidence and health care system 
“market share” metrics over a 7-year period as to minimize the impact of any year-to-
year variations (e.g., change in number of physicians, insurance contract negotiations, 
and population growth). A 95% confidence interval was constructed for each incidence 
estimate based on the Poisson distribution. Fisher’s exact test was used to calculate the 
significance of relative likelihood of gender, age, and race incidence. 
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A co-occurrence graph for the 79 ICD-9 codes (Table 1), over the five cohorts 
was constructed. Each node represents an ICD-9 code and is color-coded by its 
respective cohort. Each edge in the graph represents a co-occurrence measure 
between two nodes called the Dominant Confidence (DC) measure using the 
ForceAtlas2 algorithm23. 
Validation 
A subset of 100 patients was selected with 20 subjects chosen uniformly at 
random from within each disease cohort. No duplicate subjects were selected across 
cohorts. Traditional expert chart review was performed to determine the frequency of 
coding errors to ascertain if the ICD-9 reflected the actual diagnostic state of the 
patients.   
RESULTS 
Race, Gender, and Age Distribution of Patients 
Among the 3 397 515 residents of the defined area (market-adjusted population 
1 321 255), a total of 18 779 diagnosis incidence events were found for 18 291 unique 
patients. This number corresponds to an age adjusted incidence of 168.1/100 000 
residents (95% CI: 161.7-170.6). 
The demographics of the patients in the cohort reflected the central Tennessee 
population with 1.5% Asian, 12.8% African American, <1% Native American, 80.8% 
Caucasian, and 4.5% other/multi-racial/unknown with 2% Hispanic, 88% non-Hispanic, 
and 9% unknown. Tables 2-3 present the patient counts by race, ethnicity, and age, 
while Supplementary Table 1 presents an analysis of cohort by year. We used Fisher’s 
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exact test by doing one-vs.-rest comparison, for the relative incidence of each race 
within a disease cohort, compared to the general population. It was observed that 
Caucasians were less likely to have incidence events in all of the cohorts. African 
Americans were 1.27 times more likely to have Glaucoma, 1.95 times more likely to 
have Orbital Inflammation, and 1.23 times more likely to have Thyroid Disease. Asians 
were 1.39 times more likely to have Glaucoma, and 1.81 times more likely to have 
Thyroid Disease, but significantly less likely to have Edema or intrinsic optic nerve 
disease than other races.  
Incidence counts by gender controlled over age are shown in Supplementary 
Tables 2-6. The female to male ratio in the central TN population is almost equal (1.05). 
However, there was a clear gender bias in the patient population. Females were 1.2 
times more likely to have Glaucoma than males (p<0.05). Female population was 2.1 
times more likely to have optic nerve edema, 3.7 times more likely to have Thyroid 
Disease, and 1.3 times more likely to have intrinsic optic nerve disease (Supplementary 
Table 7). 
Similar analysis of age (Supplementary Table 8) showed that Glaucoma is 
increasingly likely after the age of 55. Intrinsic optic nerve disease is more likely in 
people over 60. The likelihood of Thyroid disease increases with age as well, with a 
peak in 45-54 age group. Whereas, optic nerve edema is most likely in young women, 
peaking in the 25-34 age group.  Orbital inflammation has the highest relative incidence 
in young children. 
Incidence Findings  
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Incidence of each of the disease cohorts did not systematically differ across the 
time period of the study (e.g., lack of apparent trends in Supplementary Table 1). For 
the remainder of the analyses, the diagnoses are pooled across years and incidence is 
scaled to reflect the increased time period. Fig. 2 shows a co-occurrence graph for the 
79 ICD-9 codes (Table 1) and table for the five cohorts. 
Validation  
For 94 of 100 patients, direct evidence of the reported ICD-9 code that led to 
cohort inclusion was found in the anonymized EMR (e.g., clinic notes, consult notes). 
Scanned handwritten notes and Adobe Portable Document Format (PDF) notes, which 
constitute a subset of the clinic and consult notes, are not included in the anonymized 
EMR due to the difficultly in removing protected health information at scale. Hence, the 
anonymized EMR is incomplete. For 5 such patients with missing notes, sufficient 
indirect evidence (including multiple entries of ICD-9 codes, medications, referrals for a 
consult, lab reports, etc.) was found such that a practicing ophthalmologist was 
convinced that the patient was legitimately diagnosed with the ICD-9 code in the chart. 
Finally, one patient had an entry of orbital cellulitis (ICD-9 376.01), but the chart showed 
periorbital cellulitis (ICD-9 373.13), which indicates a coding error sufficient so that the 
patient would have not met inclusion criteria for the orbital inflammation cohort. 
Therefore, 99 of 100 samples yielded correct cohort groups. Under a binomial model, 
the exact confidence interval on error rate is 0.02% to 5.45%, with a mean of 1%.  
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DISCUSSION 
This study provides insight into the incidence of multiple disease processes 
leading to optic nerve disease in a greater geographical area (with inclusion of patients 
from metropolitan areas and of various ethnicities) than would have been possible with 
a traditional chart review. Incidence studies of various eye diseases have been 
performed in large national health care systems such as in Beijing24 and Sweden25, and 
in a homogenous area of the United States, Olmstead county but have not been 
performed in a large metropolitan population in the United States. In the following 
sections, we discuss each cohort and the concordance of our incidence estimates with 
those reported in the literature.   
Glaucoma 
Glaucoma was by far the greatest optic nerve disease burden in the greater TN 
population. Similar to other studies, the incidence of glaucoma in the middle TN 
population dramatically increases with age over 405. We see this trend very clearly, with 
the steep increase of the relative incidence of Glaucoma after 50 in Supplemental Table 
8. The prevalence of open angle glaucoma in the United States has been estimated to 
be 2.2 million people. Our data was confined to new diagnosis of all forms of glaucoma 
and may underestimate the disease burden from glaucoma in the middle TN population. 
Chronic open angle glaucoma is the most common cause of optic neuropathy in adults 
over the age of 40 and is estimated to affect 2.2 million Americans currently, with an 
estimated 3.36 million in 20205. Race is a large factor in the risk of visual field loss and 
blindness from glaucoma. In a recent study, patients of African descent with the same 
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access to care were shown to have a hazard ratio of up to 3.61 in the development of 
visual field loss at intraocular pressures greater than 22mm Hg, as compared to patients 
of European descent26. In our patient population, we found that glaucoma had only a 
slightly higher incidence in African American population (Odds Ratio=1.27). 
Intrinsic Optic Nerve Disease 
Disease related to the optic nerve other than glaucoma were pooled into an 
intrinsic optic nerve disease category and included optic neuritis, ischemic optic 
neuropathy, arteritic optic neuropathy. Optic neuritis most often affects young, 
Caucasian females, with a mean age of 3227 with incidence of approximately 5 per 100 
0002. Anterior ischemic neuropathy, including arteritic and non-arteritic subtypes, is the 
most common cause of acute optic neuropathy in adults over the age of 50. Its 
incidence has been reported at 2-10 per 100 00010. Arteritic anterior ischemic optic 
neuropathy comprises much fewer of the cases of anterior ischemic optic neuropathy 
(5-10%) and occurs most frequently in patients over 70 years old, with an estimated 
incidence of 10-19.8 per 100 000 patients11, 12 and a peak incidence in women aged 70-
7911 By looking more broadly at the phenotype of optic neuropathies, we can appreciate 
population level trends with a great degree of accuracy. Notably, there is a moderate 
increase in incidence of optic neuropathy in females over males (13.5 versus 10.4 per 
100 000). For both males and females, the incidence of optic neuropathy is low <35 
years old and begins to increase with age. The overall levels of incidence are generally 
in agreement with the literature when factoring the multiple conditions captured in this 
cohort.  
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Optic Nerve Edema 
 The middle TN population cohort of patients with optic nerve edema included 
patients with idiopathic intracranial hypertension (IIH) and papilledema. A study of the 
incidence of IIH from 1988 reported 75 patients from 2 states and a later study from 
2004 reported 51 patients from Mississippi. The later report which was from a poster 
presentation suggests that the incidence is rising with the increase in rates of obesity, 
with about 22.5 new cases each year per 100 000 overweight women of childbearing 
age3, 28. The IIH incidence has been reported to be 0.9-2.36 per 100 0003, 13-15, though 
much higher in women3, 4, 15 with a mean age of onset at presentation of 29.4 and 
average body mass index of 39.8. With differing etiologies leading to optic nerve edema 
(including intracranial hypertension and papilledema), prior studies may have provided a 
conservative impression of the overall incidence. Here, we find age-adjusted incidences 
of 12.7 (F) and 6.0 (M) per 100 000. As with prior studies, optic nerve edema is 
substantively elevated in women of childbearing age (20-54), with 2.24 increased 
incidence for 25-34 versus the rest of the population (Supplementary Table 8). 
Incidence in males peaked at 10-14 years old (14.0 per 100 000).  
Orbital Inflammation 
The category orbital inflammation includes a variety of conditions either from an 
infectious or idiopathic etiology to include orbital cellulitis, orbital myositis, orbital 
periostitis, dacryoadenitis, and non-specific orbital inflammation (NSOI), among others. 
With the broad range of conditions that lead to orbital inflammation, systematic 
incidence studies of individual disease entities, or even pooled conditions as in this 
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study, at a population level do not appear to have been conducted with some exception 
for example sarcoidosis in the veteran population29. An increased incidence of orbital 
infection has been associated with socioeconomic deprivation30. We find substantially 
higher incidences in children and African American population (Tables 10 and 11).  
Thyroid Disease  
We note that thyroid eye disease is not precisely / completely captured by ICD-9 
diagnostic practices. Herein, we included 242.00 “Toxic diffuse goiter without mention of 
thyrotoxic crisis or storm” in the definition. While 242.00 includes eye disease resulting 
from hyperthyroidism, it is not specific. If we limit our consideration of thyroid eye 
disease to ICD-9 codes of 376.2*, these patients have definitive eye involvement, yet, 
only a small fraction of the eye patients would be found. For example, the 1523:388 
patients in Supplementary Table 6 would drop to 139:50. Hence, this study presents the 
incidence of thyroid disease as a risk factor / prodromal aspect of thyroid eye disease. 
In31, the authors found that 12.5% of thyroid patients present with eye involvement. 
Therefore, it would be reasonable to divide the thyroid disease incidence estimates by 
eight to yield a conservative estimate of thyroid eye disease. The ambiguity in clinical 
disease identification of thyroid eye disease remains in ICD-10. Thyroid eye disease 
typically presents in the setting of hyperthyroidism. Approximately 1.3% of the United 
States population is estimated to have hyperthyroid disease32. Approximately 50% of 
hyperthyroid patients have Graves’ disease and of those patients with Graves’ disease, 
approximately 25% have clinically significant thyroid eye disease33.  Optic nerve 
compression is estimated to occur in 3-5% of patients with thyroid eye disease20, 21. In 
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our cohort, 84.21% of patients had  a diagnosis of thyrotoxicosis without mention of 
thyrotoxic crisis or storm (ICD9 242.00) also had a diagnosis of endocrine 
exophthalmos (ICD9 376.2, 376.21, or 376.22). Using these US populations studies, our 
estimated calculation of patients with thyroid disease in this middle TN cohort is 34.7 
per 100 000 population. A study performed by Bartley et al detailed the incidence of 
thyroid ophthalmopathy in a cohort of patients in Minnesota, yielding 16.0 cases per 100 
000 population per year for women and 2.9 cases per 100 000 per year for men1. 
Compared with Olmsted County, middle Tennessee is more diverse and more urban; 
substantially more thyroid disease patients were identified in this study (1 523 in 7 years 
versus 519 in 15 years). The overall incidence seen in this study was approximately 
two-fold higher (versus 16.0 per 100 000 for females and 2.9 per 100 000 for males). 
We note that the Bartley study was based on manual chart review and excluded 
patients with hypothyroidism and Hashimoto's thyroiditis without ophthalmopathy, which 
could have resulted in a systematic bias between manual review and ICD-9 studies. 
Moreover, diagnostic practices and technologies have substantively evolved in the two 
decades between these two studies. In summary, the current study indicates a 
substantially greater incidence of thyroid disease in the general population than 
previous studies have indicated.  
Limitations and Conclusion 
A central limitation of the study is that incidences are reflective of physician 
diagnostic standards and insurance coding practices, which are reasonable proxy for 
true disease occurrence, but not identical. Second, the population of the target areas is 
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based on census data from a median year. We chose not to linearly interpolate between 
the census years (as in12) given the growth of the Nashville area and hesitancy to 
extrapolate population beyond the census period; rather we pool across years as to 
level out inconsistencies due to systematic factors (i.e., those that may lead to year-by-
year variations in market share). The lack of trends in incidence by year (Supp. Table 4) 
lends support to the selected study design methodology. Finally, the market share 
corrected population is based on reported inpatient data, whereas the patient cohorts 
are based on both inpatient and outpatient information. Outpatient information is not 
reportable to the state and is not available for institutions outside of the VUMC affiliated 
hospital network. If all patients had come to VUMC (and none to other hospital 
systems), incidence could not be less than a third of the reported values (1/0.389). 
Hence, small errors in market share analyses translate to small errors in incidence 
estimates. Moreover, we find that coding errors are rare for our target population 
(approximately 1:100) and would not substantively impact the incidence estimates. 
Importantly, these limitations are generally cohort- and demographic agnostic (i.e., 
would not substantively impact the reporting of one condition relative to another or one 
patient versus another). Therefore, we have high confidence in the incidence 
comparisons within and across Supplemental Tables (e.g., males versus females, age 
groups, optic nerve disease versus orbital inflammation).  
In conclusion, this manuscript has characterized the incidence of five important 
sets of pathological conditions that impact the optic nerve through use of anonymized 
EMRs. In contrast to several previous studies, we estimate the incidence of conditions 
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that are known to lead to optic nerve damage as opposed to incidence of optic nerve 
damage concomitant with diagnosis of a condition. The incidences reported in this study 
are generally higher than could be understood from the literature when individual 
conditions were more narrowly defined, or when incidence studies were performed in 
less diverse settings. Moreover, the reported incidence rates are reflective of current 
diagnostic technologies and practices.  Hence, this study serves as an important update 
on the incidence of conditions that impact the optic nerve with demographics reflective 
of the US population (with a slight under-sampling of Asian and Hispanic and 
oversampling of African American).  
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TITLES AND LEGENDS TO FIGURES 
 
Fig. 1.  Flowchart of calculation of average incidence per 100 000. 
 
Fig. 2. ICD-9 codes within a cohort have a very high co-occurrence, however there is overlap 
between diagnoses cohorts as well, as quantitatively shown in the table at right. (A) shows a co-
occurrence graph for the 79 ICD-9 codes (Table 1), over the five cohorts. Each node represents 
an ICD-9 code and is color-coded by its respective cohort. Each edge represents a co-
occurrence measure between two nodes called the Dominant Confidence (DC) measure. The 
thickness of the edge represents the magnitude of DC, i.e. a thicker edge indicates a stronger 
co-occurrence. The DC measure between A and B is given by 𝐷𝐶	 𝐴, 𝐵 = 𝑚𝑎𝑥 + ,,-+(,) , + ,,-+(-) , 
where P(A) is the probability of having diagnosis A, and P(A, B) is the probability of having both 
diagnosis A and B. The graph was created by calculating the DC measure for all 6 241 pairs of 
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ICD9 codes. The graph clustering was performed using ForceAtlas2 algorithm. The ForceAtlas2 
algorithm computes attraction and repulsion forces proportional to the weights of the edges (DC 
measures) such that nodes with high co-occurrence are clustered closer together, while nodes 
with low co-occurrence are further away from each other. ICD-9 codes within a cohort have a 
very high co-occurrence, however there is overlap between diagnoses cohorts as well, as 
quantitatively shown in the table at right. In (B), each entry of the table shows the probability of a 
patient having the column condition given that they have the condition in the row.  
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Table 1. Cohort inclusion criteria 
Cohort ICD-9 
codes 
Description 
Glaucoma 365.0*  Borderline glaucoma 
 365.1*  Open-angle glaucoma 
 365.2* Primary angle-closure glaucoma 
 365.3* Corticosteroid-induced glaucoma 
 365.4* Glaucoma associated with congenital anomalies, 
dystrophies, and systemic syndromes 
 365.5* Glaucoma associated with disorders of the lens 
 365.6* Glaucoma associated with other ocular disorders 
 365.7* Glaucoma stage, unspecified 
 365.8* Other specified forms of glaucoma 
 365.9* Unspecified glaucoma 
Intrinsic Optic Nerve 
Disease 
377.3* Optic Neuritis 
  377.4* Other disorders of optic nerve 
Papilledema 348.2 Idiopathic intracranial hypertension 
 377.0, 
377.00 
Papilledema 
 377.01 Papilledema, increased intracranial pressure 
 377.02 Papilledema, decreased ocular pressure 
Orbital Inflammation 376.0, 
376.00 
Acute inflammation of orbit 
 376.01 Orbital cellulitis 
 376.02 Orbital periostitis 
 376.1 Chronic inflammation of orbit 
 376.11 Orbital granuloma 
 376.12 Orbital myositis 
  373.13 Abscess of eyelid 
Thyroid Disease 242.00 Toxic diffuse goiter without thyrotoxic crisis or storm 
 376.2 Endocrine exophthalmos 
 376.21 Thyrotoxic exophthalmos 
 376.22 Exophthalmic ophthalmoplegia 
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TABLE II: Patient counts by race and ethnicity at VUMC 
    Glc   ON   Edema   OI   TED   Total 
Asian F M F M F M F M F M 361 
 H. 4 5 0 0 0 0 0 0 0 0 9  NH 153 121 7 3 2 2 2 4 42 11 347 
 Unk 2 2 1 0 0 0 0 0 0 0 5 
African American                     2 865 
 H. 2 3 2 1 0 0 0 0 1 0 9  NH 1 158 927 89 60 115 30 75 74 238 46 2812 
 Unk 13 16 0 3 1 1 1 1 6 2 44 
American Native                     33 
 H. 2 2 1 0 0 0 0 0 1 0 6 
 NH 13 11 0 0 0 0 1 0 2 0 27 
 Unk 0 0 0 0 0 0 0 0 0 0 0 
White 0 0 0 0 0 0 0 0 0 0 13 357 
 H. 88 64 13 16 11 9 26 21 28 14 290  NH 5 370 4 121 544 399 514 253 203 208 1 044 275 12 931 
 Unk 54 46 8 4 7 2 3 3 8 1 136 
Unknown / Other                     2 163 
 H. 25 22 3 3 1 1 3 4 8 2 72  NH 234 182 14 8 9 5 3 9 20 9 493 
 Unk 694 545 67 56 46 17 5 15 125 28 1 598 
Total 7 812 6 067 749 553 706 320 322 339 1 523 388 18 779 
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TABLE III: Patients Counts by Age Group 
 
Min Age Glc ON Edema OI TED 
0-4 111 100 42 171 14 
5-9 103 55 68 64 22 
10-14 164 44 102 65 40 
15-19 164 69 113 34 101 
20-24 156 52 83 25 89 
25-34 513 147 223 54 300 
35-44 917 176 163 73 376 
45-54 1997 188 117 62 422 
55-59 1476 85 34 29 154 
60-64 1685 92 30 25 138 
65-74 3592 152 39 40 170 
75-84 2176 109 12 11 67 
85+ 825 33 0 8 18 
 
